Floretyrosine F 18 PDE report and OEL report profile
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
178433-03-9
Molecular formula
C11H14[18F]NO3
Molecular weight
226.238 g/mol
Drug class
18F-labelled amino-acid PET radiotracerdiagnostic imaging agent
Mechanism of action
Radiolabelled fluoroethyltyrosine is transported into cells by large neutral amino acid transporters (LAT1/LAT2). Increased uptake in metabolically active tumour tissue can support PET imaging; it is a diagnostic radiopharmaceutical, not a therapeutic tyrosine analogue.
Indications / reported uses
PET imaging of brain tumours in adults with cognitive impairment or suspected glioma to assist assessment of amino-acid transport and tumour activity under the specific radiopharmaceutical product authorisation; the exact intended use is jurisdiction- and product-specific
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Floretyrosine F 18 PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Floretyrosine F 18 Permitted Daily Exposure (PDE) report (the Floretyrosine F 18 PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Floretyrosine F 18 Occupational Exposure Limit (OEL) report (the Floretyrosine F 18 OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.